{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:44:33Z","timestamp":1787024673384,"version":"build-2736575974"},"reference-count":21,"publisher":"Bentham Science Publishers Ltd.","issue":"7","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CAR"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Rivastigmine, a reversible AChEI for symptomatic treatment of mild to moderately severe Alzheimer\u2019s dementia is administered in once daily transdermal patches enabling an easier and continuous drug delivery. A novel multi-day (twice week) patch formulation with greater convenience for patients\u2019 therapeutic management, was developed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To assess the bioequivalence under SS conditions of the multiple-day rivastigmine transdermal patch (Test Product, RID-TDS) in comparison to the once daily Exelon\u00ae transdermal patch (Reference Product), both at a release rate of 9.5 mg\/24 h.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Single center, open-label, randomized, multiple dose study in healthy male adults in a 2-period, 2-sequence-crossover design with multiple applications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patches were applied on 11 consecutive days for Exelon\u00ae and 4-3-4-day regimen for the multiday test patch (RID-TDS), separated by a 14-day wash-out period. The safety, local tolerability and inhibitory effect of rivastigmine on plasma BuChE activity were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>57 subjects completed the study according to the protocol. Calculated point estimates and 90% CI for all primary parameters (AUC96-264, Cmax96-264 and Cmin96-264) were within the predefined acceptance interval of 80.00 \u2013 125.00%. They were 113.64% (107.33 \u2013 120.33), 105.14% (98.38 \u2013 112.38) and 107.82% (97.78 \u2013 118.89) respectively. Satisfactory adhesion (CI of mean adhesion above 90%) was demonstrated for RID-TDS but not for Exelon\u00ae.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Bioequivalence was demonstrated between RID-TDS mg twice a week and Exelon\u00ae once a day in SS. Patch adhesion favored RID-TDS despite the longer dosing interval. Both products were well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration number:<\/jats:title>\n                    <jats:p>Protocols are registered in ClinicalTrials.gov: NCT03659435 and EudraCT: 2018-001570-18<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1567205019666220823105059","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T06:43:25Z","timestamp":1661496205000},"page":"541-553","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparative Bioavailability Study of a Novel Multi-Day Patch Formulation\nof Rivastigmine (Twice Weekly) with Exelon\u00ae Transdermal Patch\n(Daily)- A Randomized Clinical Trial"],"prefix":"10.2174","volume":"19","author":[{"given":"Bjoern","family":"Schurad","sequence":"first","affiliation":[{"name":"Luye Pharma AG, Miesbach, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius","family":"Koch","sequence":"additional","affiliation":[{"name":"Luye Pharma AG, Miesbach, Germany"},{"name":"SocraTec R&amp;D GmbH, Erfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Schug","sequence":"additional","affiliation":[{"name":"SocraTec R&amp;D GmbH, Erfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaida","family":"Morte","sequence":"additional","affiliation":[{"name":"ESTEVE Pharmaceuticals SA, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vaqu\u00e9","sequence":"additional","affiliation":[{"name":"ESTEVE Pharmaceuticals SA, Barcelona,\nSpain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6765-1866","authenticated-orcid":true,"given":"Rafael","family":"De la Torre","sequence":"additional","affiliation":[{"name":"Research Group in Integrated Pharmacology and Systems Neuroscience, Hospital del Mar Research\nInstitute Doctors (IMIM), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Iniesta","sequence":"additional","affiliation":[{"name":"ESTEVE Pharmaceuticals SA, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/1179573520907397","author":"Yiannopoulou K.G.","year":"2020","unstructured":"Yiannopoulou K.G.; Papageorgiou S.G.; Current and future treatments in Alzheimer\u2019s disease: An update. J Cent Nerv Syst Dis 2020,12","journal-title":"J Cent Nerv Syst Dis"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.3390\/biomedicines9121910","volume":"9","author":"Garc\u00eda-Morales V.","year":"2021","unstructured":"Garc\u00eda-Morales V.; Gonz\u00e1lez-Acedo A.; Melguizo-Rodr\u00edguez L.; Current understanding of the physiopathology, diagnosis and therapeutic approach to Alzheimer\u2019s disease. Biomedicines 2021,9(12),1910","journal-title":"Biomedicines"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","volume":"141","author":"Hampel H.","year":"2018","unstructured":"Hampel H.; Mesulam M.M.; Cuello A.C.; The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease. Brain 2018,141(7),1917-1933","journal-title":"Brain"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2165\/00002512-200825040-00001","volume":"25","author":"Kaestli L.Z.","year":"2008","unstructured":"Kaestli L.Z.; Wasilewski-Rasca A.F.; Bonnabry P.; Vogt-Ferrier N.; Use of transdermal drug formulations in the elderly. Drugs Aging 2008,25(4),269-280","journal-title":"Drugs Aging"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3233\/ADR-210307","volume":"5","author":"Yunusa I.","year":"2021","unstructured":"Yunusa I.; Alsahali S.; Rane A.; Eguale T.; Comparative value of cholinesterase inhibitors and memantine in persons with moderate-to-severe Alzheimer\u2019s disease in the united states: A cost-effectiveness analysis. J Alzheimers Dis Rep 2021,5(1),705-713","journal-title":"J Alzheimers Dis Rep"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/2042098617750555","volume":"9","author":"Khoury R.","year":"2018","unstructured":"Khoury R.; Rajamanickam J.; Grossberg G.T.; An update on the safety of current therapies for Alzheimer\u2019s disease: Focus on rivastigmine. Ther Adv Drug Saf 2018,9(3),171-178","journal-title":"Ther Adv Drug Saf"},{"key":"ref=7","unstructured":"Exelon Procedure No: EMEA\/H\/C\/169\/X\/38 Scientific Discussion 2007. Available from:"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1592\/phco.20.1.1.34664","volume":"20","author":"Jann M.W.","year":"2000","unstructured":"Jann M.W.; Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer\u2019s disease. Pharmacotherapy 2000,20(1),1-12","journal-title":"Pharmacotherapy"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jchromb.2007.01.003","volume":"852","author":"Bhatt J.","year":"2007","unstructured":"Bhatt J.; Subbaiah G.; Kambli S.; A rapid and sensitive liquid chromatography\u2013tandem mass spectrometry (LC\u2013MS\/MS) method for the estimation of rivastigmine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007,852(1-2),115-121","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1002\/rcm.2737","volume":"20","author":"Frankfort S.V.","year":"2006","unstructured":"Frankfort S.V.; Ouwehand M.; Maria J van Maanen, Hilde Rosing, Linda R Tulner, Jos H Beijnen. A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry. Rapid Commun Mass Spectrom 2006,20(22),3330-3336","journal-title":"Rapid Commun Mass Spectrom"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S1570-0232(02)00816-4","volume":"784","author":"Pommier F.","year":"2003","unstructured":"Pommier F.; Frigola R.; Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003,784(2),301-313","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref=12","unstructured":"EMA: Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms, EMA\/CHMP\/EWP\/280\/96 Rev1 2014. Available from:"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","volume":"7","author":"Ellman G.L.","year":"1961","unstructured":"Ellman G.L.; Courtney K.D.; Andres V.; Featherstone R.M.; A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961,7(2),88-95","journal-title":"Biochem Pharmacol"},{"key":"ref=14","unstructured":"FDA: Bioanalytical Method Validation Guidance for Industry. May 2018. Available from:"},{"key":"ref=15","unstructured":"EMEA: Guideline on bioanalytical method validation. MEA\/CHMP\/EWP\/192217\/2009 Rev. 1 Corr. 2*21 July 2011. Available from:"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/sj.clpt.6100242","volume":"83","author":"Lef\u00e8vre G","year":"2008","unstructured":"Lef\u00e8vre G; S\u0119dek G, Jhee SS, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer\u2019s disease patients. Clin Pharmacol Ther 2008,83(1),106-114","journal-title":"Clin Pharmacol Ther"},{"key":"ref=17","unstructured":"EMA: Guideline on the investigation of bioequivalence, CPMP\/EWP\/QWP\/1401\/98 Rev. 1\/ Corr **. 2010. Available from:"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1177\/0091270006297748","volume":"47","author":"Lef\u00e8vre G","year":"2007","unstructured":"Lef\u00e8vre G; S\u0119dek G, Huang HLA, et al. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: Relative effects of body site application. J Clin Pharmacol 2007,47(4),471-478","journal-title":"J Clin Pharmacol"},{"key":"ref=19","author":"Exxelon F.","unstructured":"Exxelon F.;  Exxelon, fachinformation Exelon\u00ae transdermales Pflaster. Novartis Pharma. 2018. Available from:"},{"key":"ref=20","unstructured":"Clinical Study Report \u2013 final, 2019-09-12 \u2013 1352riv18ct. EudraCTNo.: 2018-001570-18. Open, randomized, 2-period, 2-sequence, cross-over relative bioavailability study to investigate the pharmacokinetics and to assess the bioequivalence of a rivastigmine test patch formulation 9.5 mg\/24 h (twice weekly patch) compared to the reference Exelon\u00ae 9.5 mg\/24 h (once daily patch) applied for 11 days."},{"key":"ref=21","unstructured":"Clinical Study Report \u2013 final, 2015-04-20\u2013 1293riv14ct. EudraCTNo.: 2014-001201-40. Open, randomized, 2-period, 2-sequence, cross-over proof-of concept study to investigate relative bioavailability and pharmacodynamic effect of a test transdermal patch formulation of rivastigmine compared with Exelon\u00ae transdermal patch with a release rate of 4.6 mg\/24 h in healthy subjects."}],"container-title":["Current Alzheimer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567205019666220823105059","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/207901\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567205019666220823105059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T17:30:28Z","timestamp":1691775028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/207901\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567205019666220823105059","relation":{},"ISSN":["1567-2050"],"issn-type":[{"value":"1567-2050","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-05-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}